Shares of Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty-five research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $66.0556.
BMY has been the subject of several recent analyst reports. Citigroup reissued a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price on the stock in a research note on Wednesday, August 5th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th.
Key Headlines Impacting Bristol Myers Squibb
- Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
- Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
- Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
- Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
- Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
- Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares
Bristol Myers Squibb Price Performance
NYSE BMY opened at $66.62 on Monday. The company has a 50-day moving average price of $61.76 and a two-hundred day moving average price of $59.68. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $68.64. The stock has a market cap of $136.09 billion, a price-to-earnings ratio of 14.67, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts forecast that Bristol Myers Squibb will post 6.95 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s payout ratio is presently 55.51%.
Insider Buying and Selling
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.05% of the company’s stock.
Institutional Investors Weigh In On Bristol Myers Squibb
Hedge funds have recently modified their holdings of the stock. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb in the 4th quarter worth about $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $25,000. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb in the second quarter worth about $27,000. Bayban acquired a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
See Also
- Five stocks we like better than Bristol Myers Squibb
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
